While expectations are growing that Takeda Pharmaceutical Co. Ltd. will formally bid to acquire Shire PLC, market analysts are feverishly modeling all the options, and in addition to increasing odds for mega-merger specialist Pfizer Inc., at least one analyst is making a solid case for Amgen Inc. to buy out the Irish specialty pharma.
Shire's Suitors: Takeda, Pfizer Seen As Likely To Bid; Amgen Could Enter Fray
Takeda indicates to analysts that it is warming to idea of buying Shire, but do Pfizer or Amgen make greater sense to acquire the rare disease specialist?
More from Deals
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
More from Business
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.